T cell specificity and cross reactivity towards enterobacteria, Bacteroides, Bifidobacterium, and antigens from resident intestinal flora in humans

Gut

Volumn 44, Issue 6, 1999, Pages 812-818

  Duchmann, R ^a   May, E ^a   Heike, M ^a   Knolle, P ^a   Neurath, M ^a   Meyer Zum Buschenfelde K H ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Inflammatory bowel disease; Intestinal flora; Mucosal immunity; T cells

Indexed keywords

BACTERIAL ANTIGEN; CD4 ANTIGEN; PHYTOHEMAGGLUTININ; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ADULT; AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ARTICLE; BACTEROIDES; CELL SPECIFICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; ENTEROBACTERIACEAE; ENTEROCOLITIS; FEMALE; HUMAN; HUMAN CELL; INTESTINE FLORA; LACTOBACILLUS BIFIDUS; LYMPHOCYTE CLONE; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0032982463     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.44.6.812     Document Type: Article

References (52)

1. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. J Immunol 1996;157:1261-70.
2. Schreiber S, MacDermott RP, Raedler A, et al. Increased activation of isolated intestinal lamina propria mononuclear cells in inflammatory bowel disease. Gastroenterology 1991;101:1020-30.
3. Duchmann R, Strober W, Fiocchi C, et al. T cell receptor Vβ gene expression in IBD lamina propria lymphocytes: evidence for altered Vβ gene usage. Inflammatory Bowel Diseaes 1995;1:184-92.
4. Probert CS, Chott A, Turner JR, et al. Persistent clonal expansion of peripheral blood CD4+ lymphocytes in chronic inflammatory bowel disease. J Immunol 1996;157:3183-91.
5. Sartor RB. Role of the intestinal microflora in pathogenesis and complications. In: Schölmerich J, Kruis W, Goebell H, et al, eds. Inflammatory bowel diseases: pathophysiology as basis of treatment. Lancaster: Kluwer Academic, 1992:175-87.
6. Simon GL, Gorbach SL. Intestinal flora in health and disease. Gastroenterology 1981;86:174-93.
7. Peach S, Drasar B, Hawley P, et al. Mucosal flora of the human colon. Gut 1975;16:824.
8. Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991;338:771-4.
9. Wyatt J, Vogelsang H, Hubl W, et al. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993;341:1437-41.
10. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991;32:1071-5.
11. Turunen U. A double-blind, placebo-controlled, six months ciprofloxacin treatment improves prognosis in ulcerative colitis [abstract]. Gastroenterology 1991;106:A786a.
12. Graham DY, Al-Alassi MT, Robinson M. Prolonged remission in Crohn's disease following therapy for Mycobacterium paratuberculosis infection [abstract]. Gastroenterology 1995;198:A826a.
13. Peppercorn MA. Is there a role for antibiotics as primary therapy in Crohn's ileitis? J Clin Gastroenterol 1993;17:235-7.
14. Pirzer U, Schönhaar A, Fleischer B, et al. Reactivity of infiltrating T lymphocytes with microbial antigens in Crohn's disease. Lancet 1991;338:1238-9.
15. Duchmann R, Märker-Hermann E, Meyer zum Büschenfelde KH. Bacteria-specific T-cell clones are selective in their reactivity towards different Enterobacteria or H. pylori and increased in inflammatory bowel disease. Scand J Immunol 1996;44:71-9.
16. Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995;102:448-55.
17. Sartor R, Cromartie W, Powell D, et al. Granulomatous enterocolitis induced in rats by purified bacterial cell wall fragments. Gastroenterology 1985;89:587-95.
18. Mee A, McLaughlin J, Hodgson H, et al. Chronic immune colitis in rabbits. Gut 1970;20:1-5.
19. Robert A, Asano T. Resistance of germ-free rats to indomethacin-induced intestinal lesions. Prostaglandins 1977;14:333-41.
20. Bjarnason I, Hayllar J, Smethurst P, et al. Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy. Gut 1992;33:1204-8.
21. Sadlack B, Merz H, Schorle H, et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75:253-61.
22. Kühn R, Löhler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263-74.
23. Hammer RE, Maika SD, Richardson JA, et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 1990;63:1099-112.
24. Rath HC, Herfarth HH, Ikeda JS, et al. Normal luminal bacteria, especially bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27 human β2 microglobulin transgenic rats. J Clin Invest 1996;98;945-53.
25. Onderdonk AB, Franklin ML, Cisneros RL. Production of experimental ulcerative colitis in gnotobiotic guinea pigs with simplified microflora. Infect Immun 1981;32:225-31.
26. Gardiner KR, Anderson NH, Rowlands BJ, et al. Colitis and colonic mucosal barrier dysfunction. Gut 1995;37:530-5.
27. Gardiner KR, Erwin PJ, Anderson NH, et al. Colonic bacteria and bacterial translocation in experimental colitis. Br J Surg 1993;80:512-16.
28. Duchmann R, Schmitt E, Knolle P, et al. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 and antibodies to interleukin-12. Eur J Immunol 1996;26:934-8.
29. Garcia-Lafuente A, Antolin M, Crespo E, et al. Bacterial strains of enteric origin decrease mucosal hydrophobicity and intensify colonic injury by hydrophilic toxins [abstract]. Gastroenterology 1996;110:A913
30. Neurath M, Fuss I, Kelsall BL, et al. Antibodies to IL-12 abrogate established granulomatous colitis in mice. J Exp Med 1995;182:1281-90.
31. Neurath MF, Fuss I, Kelsall B, et al. Experimental granulomatous colitis in mice is abrogated by induction of TGF-β-mediated oral tolerance. J Exp Med 1996;183:2605-16.
32. Videla S, Vilaseca J, Guarner F, et al. Role of intestinal microflora in chronic inflammation and ulceration of the rat colon. Gut 1994;35:1090-7.
33. de Dombal FT, Burton IL, Clamp SE, et al. Short-term course and prognosis of Crohn's disease. Gut 1974;15:435-43.
34. Truelove SC, Witts IJ. Cortisone in ulcerative colitis. BMJ 1955;2:1042-8.
35. Duchmann R, Strober W, James SP. Quantitative measurement of human TCR-Vβ subfamilies by reverse transcription-polymerase chain reaction using synthetic internal mRNA standards. DNA Cell Biol 1993;12:217-25.
36. Hermann E, Fleischer B, Mayet W, et al. Response of synovial fluid T cell clones to Yersinia enterocolitica antigens in patients with yersinia arthritis. Clin Exp Immunol 1989;75:365-70.
37. Keighley MRB, Arabi Y, Dimock F, et al. Influence of inflammatory bowel disease on intestinal microflora. Gut 1979;19:1099-104.
38. Giaffer MH, Holdsworth CD, Duerden BI. Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease. Gut 1992;33:646-50.
39. Krook A, Lindstrom B, Kjellander J, et al. Relation between concentrations of metronidazole and Bacteroides spp in facces of patients with Crohn's disease and healthy individuals. J Clin Pathol 1981;34:165-50.
40. Van de Merwe JP, Schroder AM, Wensinck F, et al. The obligate anaerobic faecal flora of patients with Crohn's disease and their first-degree relatives. Scand J Gastroenterol 1988;23:1125-31.
41. Van de Merwe JP, Stegeman JH, Hazenber MP. The resident fecal flora is determined by genetic characteristics of the host. Implications for Crohn's disease? Antome van Leeuwenhook 1983;49:119.
42. Ruseler van Embden JG, Both Patori, HC. Anaerobic gram-negative faecal flora in patients with Crohn's disease and healthy subjects. Antonie Van Leeuwenhook 1983;49:125-32.
43. Auer IO, Roder A, Wensinck F, et al. Selected bacterial antibodies in Crohn's disease and ulcerative colitis. Scand J Gastroenterol 1983;18:217-23.
44. Kersten CM, McCluskey RT, Shaw WH, et al. Responses of human T cells to dominant discrete protein antigens of Escherichia coli and Pseudomonas aeruginosa. Scand J Immunol 1994;40:151-7.
45. Tommaso AD, Xiang Z, Bugnoli M, et al. Helicobacter pylori-specific CD4+ T cell clones from peripheral blood and gastric biopsies. Infect Immun 1995;63:1102-6.
46. Kersten CM, McCluskey RT, Boyle LA, et al. Escherichia coli and Pseudomonas aeruginosa induce expansion of Vδ2 cells in adult peripheral blood, but of Vδ1 cells in cord blood. J Immunol 1996;157:1613-19.
47. Foo MC, Lee A. Antigenic cross-reaction between mouse intestine and a member of the autochthonous microflora. Infect Immun 1974;9:1066-9.
48. Rodloff AC, Widera P, Ehlers S, et al. Suppression of blastogenic transformation of lymphocytes by Bacteroides fragilis in vitro and in vivo. Int J Med Microbiol 1990;274:406-16.
49. Wells CL, van de Westerlo E, Jechorek RP, et al. Bacteroides fragilis enterotoxin modulates epithelial permeability and bacterial internalization by HT-29 enterocytes. Gastroenterology 1996;110:1429-37.
50. Bernet MF, Brassart D, Neeser JR, et al. Adhesion of human bifidobacterial strains to cultured human intestinal epithelial cells and inhibition of enteropathogen-cell interactions. Appl Environ Microbiol 1993;59:4121-8.
51. Gibson GR, Wang X. Regulatory effects of bifidobacteria on the growth of other colonic bacteria. J Appl Bacteriol 1994; 77:412-20.
52. Saavedra JM, Bauman NA, Oung I, et al. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994;344:1046-9.